Dual target inhibitors based on EGFR: Promising anticancer agents for the treatment of cancers (2017-)

Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure–activity relationship and biological activity as potential antitumor and anticonvulsant agents

(2021) Phoebe F. Lamie et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

FGFR-TKI resistance in cancer: current status and perspectives

(2021) Sitong Yue et al.   Journal of Hematology & Oncology

The basic route of nuclear‐targeted transport of IGF‐1/IGF‐1R and potential biological functions in intestinal epithelial cells

(2021) Ming Xiu et al.   CELL PROLIFERATION

Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors

(2021) Bin Zhang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Diversity of insulin and IGF signaling in breast cancer: Implications for therapy

(2021) Michael W. Lero et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

AKT Inhibitors: New Weapons in the Fight Against Breast Cancer?

(2021) Federica Martorana et al.   Frontiers in Pharmacology

Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers

(2021) Min Zou et al.   BIOORGANIC CHEMISTRY

Design, synthesis and biological evaluation of 2,3-dihydroimidazo[2,1-b]thiazoles as dual EGFR and IGF1R inhibitors

(2021) Pradip K. Gadekar et al.   BIOORGANIC CHEMISTRY

Aurora kinase inhibitors as potential anticancer agents: Recent advances

(2021) Tathagata Pradhan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold

(2020) Min Sun et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Tubulin Proteins in Cancer Resistance: A review

(2020) Mohammad A. Kamal et al.   CURRENT DRUG METABOLISM

Recent Advances in Multi-target Drugs Targeting Protein Kinases and Histone Deacetylases in Cancer Therapy

(2020) Yong Ling et al.   CURRENT MEDICINAL CHEMISTRY

Compound 15c, a Novel Dual Inhibitor of EGFRL858R/T790M and FGFR1, Efficiently Overcomes Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance of Non-Small-Cell Lung Cancers

(2020) Gaozhi Chen et al.   Frontiers in Pharmacology

Potent dual EGFR/Her4 tyrosine kinase inhibitors containing novel (1,2-dithiolan-4-yl)acetamides

(2020) Tarek S. Mansour et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Single and dual target inhibitors based on Bcl-2: Promising anti-tumor agents for cancer therapy

(2020) Tingting Liu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells

(2020) Abderrahim El Guerrab et al.   Scientific Reports

Recent advances in inhibitors of C-terminal SRC kinase

(2020) Daniel P O’Malley   Future Medicinal Chemistry

The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy

(2020) Yubo Wang et al.   LUNG CANCER

The combination of histone deacetylase inhibitors and radiotherapy: a promising novel approach for cancer treatment

(2020) Ekta Shirbhate et al.   Future Oncology

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective

(2020) Yuan Gao et al.   BIOCHEMICAL PHARMACOLOGY

Discovery of CAPE derivatives as dual EGFR and CSK inhibitors with anticancer activity in a murine model of hepatocellular carcinoma

(2020) Xiaoyu Liu et al.   BIOORGANIC CHEMISTRY

Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment

(2020) Xiaopeng Peng et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors

(2019) Romeo Romagnoli et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis

(2019) Mai Maher et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer

(2019) Lara Kujtan et al.   Expert Review of Anticancer Therapy

Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer

(2019) J. Gao et al.   Clinical & Translational Oncology

AKT as a Therapeutic Target for Cancer

(2019) Mengqiu Song et al.   CANCER RESEARCH

FGFR1 Cooperates with EGFR in Lung Cancer Oncogenesis, and Their Combined Inhibition Shows Improved Efficacy

(2019) Alvaro Quintanal-Villalonga et al.   Journal of Thoracic Oncology

Lead generation of 1,2-dithiolanes as exon 19 and exon 21 mutant EGFR tyrosine kinase inhibitors

(2019) Tarek S. Mansour et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer

(2019) Qiming Wang et al.   Journal of Hematology & Oncology

Design, Synthesis and Biological Evaluation of Novel Osimertinib-Based HDAC and EGFR Dual Inhibitors

(2019) Hang Dong et al.   MOLECULES

The FGF metabolic axis

(2019) Xiaokun Li   Frontiers of Medicine

Facts and New Hopes on Selective FGFR Inhibitors in Solid Tumors

(2019) Francesco Facchinetti et al.   CLINICAL CANCER RESEARCH

Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors

(2019) Huiqiang Wei et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC

(2019) Eman M.E. Dokla et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents

(2019) Alessandro Rossi et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR

(2019) Wen-Xue Sun et al.   BIOORGANIC & MEDICINAL CHEMISTRY

New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies

(2019) Nehad A. El-Sayed et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1

(2018) Hongsheng Wang et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Molecular dynamics guided development of indole based dual inhibitors of EGFR (T790M) and c-MET

(2018) Pankaj Kumar Singh et al.   BIOORGANIC CHEMISTRY

Dual EGFR/HER2 inhibitors and apoptosis inducers: New benzo[ g ]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers

(2018) Mostafa M. Ghorab et al.   BIOORGANIC CHEMISTRY

Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC

(2018) Xue Li et al.   CANCER LETTERS

Recent advances in trimethoxyphenyl (TMP) based tubulin inhibitors targeting the colchicine binding site

(2018) Ling Li et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and anticancer evaluation of novel spirobenzo[ h ]chromene and spirochromane derivatives with dual EGFR and B-RAF inhibitory activities

(2018) Shaimaa A. Abdelatef et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Identification of novel N 1 -(2-aryl-1, 3-thiazolidin-4-one)- N 3 -aryl ureas showing potent multi-tyrosine kinase inhibitory activities

(2018) Baohui Qi et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis of a novel 4-O-methylsaucerneol analogue LXY7824 as potent HIF-1 inhibitor and anti-cancer agent

(2018) Xiao-Yu Liu et al.   JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH

Expressions and clinical significance of HER4 and CD44 in sinonasal mucosal malignant melanoma

(2018) Wenjia Zhu et al.   MELANOMA RESEARCH

C-terminal Src kinase (Csk) regulates the tricellular junction protein Gliotactin independent of Src

(2018) G. D. N. Gayathri Samarasekera et al.   MOLECULAR BIOLOGY OF THE CELL

Hypoxia Promotes Resistance to EGFR Inhibition in NSCLC Cells via the Histone Demethylases, LSD1 and PLU-1

(2018) Yuhong Lu et al.   MOLECULAR CANCER RESEARCH

Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi

(2018) Amila Suraweera et al.   Frontiers in Oncology

Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities – Part 1

(2018) Debasis Das et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Cyclooxygenase-2 in cancer: A review

(2018) Nasser Hashemi Goradel et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Mechanism of Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors and a Potential Treatment Strategy

(2018) Tatsuya Nagano et al.   Cells

Design, synthesis, in silico pharmacokinetics prediction and biological evaluation of 1,4-dihydroindeno[1,2-c]pyrazole chalcone as EGFR /Akt pathway inhibitors

(2018) Irfan Khan et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC

(2017) Lingfeng Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of a potent dual ALK and EGFR T790M inhibitor

(2017) Jaebong Jang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2

(2017) Hai-Qi Zhang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance

(2017) Harun Patel et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors

(2017) Mansour S. Alsaid et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and Src kinase inhibitors for antitumor treatment

(2017) Zhishan Cui et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of N -(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC

(2017) Yongfei Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants

(2017) Haixing Guan et al.   Future Medicinal Chemistry

Clinical significance of overexpression of NRG1 and its receptors, HER3 and HER4, in gastric cancer patients

(2017) Sumi Yun et al.   Gastric Cancer

Early emergence of negative regulation of the tyrosine kinase Src by the C-terminal Src kinase

(2017) Barbara Taskinen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Design, synthesis and biological activity of N4-phenylsubstituted-7H-pyrrolo[2,3-d]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase

(2017) Sonali Kurup et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance

(2017) Tim Fischer et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

First Bispecific Inhibitors of the Epidermal Growth Factor Receptor Kinase and the NF-κB Activity As Novel Anticancer Agents

(2017) Mostafa M. Hamed et al.   JOURNAL OF MEDICINAL CHEMISTRY

Caffeic acid phenethyl ester upregulates N-myc downstream regulated gene 1 via ERK pathway to inhibit human oral cancer cell growth in vitro and in vivo

(2017) Li-Chuan Chung et al.   MOLECULAR NUTRITION & FOOD RESEARCH

Design and Discovery of Quinazoline- and Thiourea-Containing Sorafenib Analogs as EGFR and VEGFR-2 Dual TK Inhibitors

(2017) Shaofeng Sun et al.   MOLECULES

Design, Synthesis and Cytotoxic Evaluation of Novel Chalcone Derivatives Bearing Triazolo[4,3-a]-quinoxaline Moieties as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects

(2017) Mohamed Alswah et al.   MOLECULES

A Phase I Dose‐Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors

(2017) Stephen Leong et al.   ONCOLOGIST

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

(2017) Ken Uchibori et al.   Nature Communications

Synthesis of 4-Anilinoquinazoline-Derivative Dual Kinase Inhibitors Targeting EGFR and VEGFR-2

(2017) Keuk Chan Bang et al.   BULLETIN OF THE KOREAN CHEMICAL SOCIETY

Light-Activated Hypoxia-Responsive Nanocarriers for Enhanced Anticancer Therapy

(2016) Chenggen Qian et al.   ADVANCED MATERIALS

Small Molecule T315 Promotes Casitas B-Lineage Lymphoma–Dependent Degradation of Epidermal Growth Factor Receptor via Y1045 Autophosphorylation

(2016) Kuo-Yen Huang et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Recent Advances in Heterocyclic Tubulin Inhibitors Targeting the Colchicine Binding Site

(2016) Xiaoxin Wu et al.   Anti-Cancer Agents in Medicinal Chemistry

Design, synthesis and evaluation of acridine derivatives as multi-target Src and MEK kinase inhibitors for anti-tumor treatment

(2016) Zhishan Cui et al.   BIOORGANIC & MEDICINAL CHEMISTRY

The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer

(2016) Jennifer L. Hsu et al.   CANCER AND METASTASIS REVIEWS

The platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) are major players in oncogenesis, drug resistance, and attractive oncologic targets in cancer

(2016) Ying Wang et al.   GROWTH FACTORS

FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)

(2016) MASARU KATOH   INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE

Development of Autotaxin Inhibitors: An Overview of the Patent and Primary Literature

(2016) Diana Castagna et al.   JOURNAL OF MEDICINAL CHEMISTRY

Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer

(2016) Zhendong Song et al.   JOURNAL OF MEDICINAL CHEMISTRY

Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer

(2016) Masayoshi Miyawaki et al.   MOLECULAR CANCER RESEARCH

Design and Synthesis of Vandetanib Derivatives Containing Nitroimidazole Groups as Tyrosine Kinase Inhibitors in Normoxia and Hypoxia

(2016) Huiqiang Wei et al.   MOLECULES

Dual MET/EGFR therapy leads to complete response and resistance prevention in a MET-amplified gastroesophageal xenopatient cohort

(2016) M Apicella et al.   ONCOGENE

1,3,4-Oxadiazole derivatives as potential antitumor agents: discovery, optimization and biological activity valuation

(2016) Yin Luo et al.   MedChemComm

TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells

(2016) D-W Wu et al.   Cell Death & Disease

Cyclooxygenase-2: A Role in Cancer Stem Cell Survival and Repopulation of Cancer Cells during Therapy

(2016) Lisa Y. Pang et al.   Stem Cells International

Discovery of a novel class anti-proliferative agents and potential inhibitors of EGFR tyrosine kinases based on 4-anilinotetrahydropyrido[4,3-d]pyrimidine scaffold: Design, synthesis and biological evaluations

(2015) Yong Zhang et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Activation of EGFR Bypass Signaling by TGF  Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells

(2015) T. Tani et al.   MOLECULAR CANCER THERAPEUTICS

Aurora Kinase Inhibitors in Oncology Clinical Trials: Current State of the Progress

(2015) Gerald S. Falchook et al.   SEMINARS IN ONCOLOGY

The importance of Src signaling in sarcoma

(2015) QUANCHI CHEN et al.   Oncology Letters

Spirochromone-chalcone conjugates as antitubercular agents: synthesis, bio evaluation and molecular modeling studies

(2015) M. Mujahid et al.   RSC Advances

Synthesis, molecular modeling, and biological evaluation of quinazoline derivatives containing the 1,3,4-oxadiazole scaffold as novel inhibitors of VEGFR2

(2015) Fang Qiao et al.   RSC Advances

NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer

(2015) Collin M. Blakely et al.   Cell Reports

Design, Synthesis, and Biological Evaluation of Hydrazone Incorporated 1,2,4-Triazines as Anticonvulsant Agents

(2014) Mohammed Amir et al.   ARCHIV DER PHARMAZIE

Chalcone based azacarboline analogues as novel antitubulin agents: Design, synthesis, biological evaluation and molecular modelling studies

(2014) Sahil Sharma et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

LPA receptor signaling: pharmacology, physiology, and pathophysiology

(2014) Yun C. Yung et al.   JOURNAL OF LIPID RESEARCH

Synthesis, Structure–Activity Relationship Studies, and Antibacterial Evaluation of 4-Chromanones and Chalcones, as Well as Olympicin A and Derivatives

(2014) Li Feng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Polypharmacology: Challenges and Opportunities in Drug Discovery

(2014) Andrew Anighoro et al.   JOURNAL OF MEDICINAL CHEMISTRY

Anticonvulsant activity of 1,2,4-triazine derivatives with pyridyl side chain: synthesis, biological, and computational study

(2014) Hamid Irannejad et al.   MEDICINAL CHEMISTRY RESEARCH

A Synthetic Manassantin A Derivative Inhibits Hypoxia-Inducible Factor 1 and Tumor Growth

(2014) Liwei Lang et al.   PLoS One

Functional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancers

(2013) Kai Hung Tiong et al.   APOPTOSIS

Does a Single Nucleotide Polymorphism in the FGFR Explain the Connection between Diabetes and Cancer?

(2013) Emily J. Gallagher et al.   Cell Metabolism

Characteristics of Lung Cancers Harboring NRAS Mutations

(2013) K. Ohashi et al.   CLINICAL CANCER RESEARCH

Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors

(2013) Maria Letícia de Castro Barbosa et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Autotaxin inhibitors: a patent review

(2013) Efrosini Barbayianni et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

(2013) Ethan V. Abel et al.   JOURNAL OF CLINICAL INVESTIGATION

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung Cancer

(2013) M. J. Niederst et al.   Science Signaling

Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis

(2013) Yihai Cao   TRENDS IN MOLECULAR MEDICINE

Platelet-derived growth factors and their receptors: Structural and functional perspectives

(2012) Po-Han Chen et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS

Design, synthesis and biological activities of sorafenib derivatives as antitumor agents

(2012) Jianwen Yao et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Caffeic Acid Phenethyl Ester Suppresses the Proliferation of Human Prostate Cancer Cells through Inhibition of p70S6K and Akt Signaling Networks

(2012) C.-P. Chuu et al.   Cancer Prevention Research

Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization

(2012) Yibing Shan et al.   CELL

Designed Multiple Ligands: Basic Research vs Clinical Outcomes

(2012) L. Costantino et al.   CURRENT MEDICINAL CHEMISTRY

Exploring Pharmacological Significance of Chalcone Scaffold: A Review

(2012) N. K. Sahu et al.   CURRENT MEDICINAL CHEMISTRY

Molecular Mechanisms and Modulation of Key Pathways Underlying the Synergistic Interaction of Sorafenib with Erlotinib in Non-Small-Cell-Lung Cancer (NSCLC) Cells

(2012) E. Giovannetti et al.   CURRENT PHARMACEUTICAL DESIGN

Regulation of the Src Family Kinases by Csk

(2012) Masato Okada   International Journal of Biological Sciences

Targeted therapy for triple-negative breast cancer: Where are we?

(2012) Michael J. Duffy et al.   INTERNATIONAL JOURNAL OF CANCER

Vascular Endothelial Growth Factor (VEGF) Receptors: Drugs and New Inhibitors

(2012) Francesca Musumeci et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and antitumor studies of novel benzopyrano-1,2,3-selenadiazole and spiro[benzopyrano]-1,3,4-thiadiazoline derivatives

(2012) S. I. El-Desoky et al.   MEDICINAL CHEMISTRY RESEARCH

Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer

(2012) T. Nakagawa et al.   MOLECULAR CANCER THERAPEUTICS

An FGFR antibody with long-lasting effects

(2012) Charlotte Harrison   NATURE REVIEWS DRUG DISCOVERY

EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

(2012) Ryan B. Corcoran et al.   Cancer Discovery

EGFR Mutations and Lung Cancer

(2011) Gilda da Cunha Santos et al.   Annual Review of Pathology-Mechanisms of Disease

Synthesis, biological evaluation, and molecular modeling of cinnamic acyl sulfonamide derivatives as novel antitubulin agents

(2011) Yin Luo et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Caffeic acid phenethyl ester (CAPE), derived from a honeybee product propolis, exhibits a diversity of anti-tumor effects in pre-clinical models of human breast cancer

(2011) Jing Wu et al.   CANCER LETTERS

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors

(2011) T. Sasaki et al.   CANCER RESEARCH

Hypoxia Predicts Aggressive Growth and Spontaneous Metastasis Formation from Orthotopically Grown Primary Xenografts of Human Pancreatic Cancer

(2011) Q. Chang et al.   CANCER RESEARCH

Identification and Characterization of a Novel Integrin-Linked Kinase Inhibitor

(2011) Su-Lin Lee et al.   JOURNAL OF MEDICINAL CHEMISTRY

Synthesis and evaluation of novel stearoyl-CoA desaturase 1 inhibitors: 1′-{6-[5-(pyridin-3-ylmethyl)-1,3,4-oxadiazol-2-yl]pyridazin-3-yl}-3,4-dihydrospiro[chromene-2,4′-piperidine] analogs

(2010) Yoshikazu Uto et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

High expression of AURKA and AURKB is associated with unfavorable cytogenetic abnormalities and high white blood cell count in patients with acute myeloid leukemia

(2010) Antonio R. Lucena-Araujo et al.   LEUKEMIA RESEARCH

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

(2010) Shivanni Kummar et al.   NATURE REVIEWS DRUG DISCOVERY

[4-(6,7-Disubstituted quinazolin-4-ylamino)phenyl] carbamic acid esters: a novel series of dual EGFR/VEGFR-2 tyrosine kinase inhibitors

(2010) Antonio Garofalo et al.   MedChemComm

Targeting epigenetic networks with polypharmacology: a new avenue to tackle cancer

(2010) Gianluigi Franci et al.   Epigenomics

A boronic acid chalcone analog of combretastatin A-4 as a potent anti-proliferation agent

(2009) Yali Kong et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Discovery of 4-anilino-N-methylthieno[3,2-d]pyrimidines and 4-anilino-N-methylthieno[2,3-d]pyrimidines as potent apoptosis inducers

(2009) William Kemnitzer et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Pharmacokinetics of caffeic acid phenethyl ester and its catechol-ring fluorinated derivative following intravenous administration to rats

(2009) Xinyu Wang et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

(2009) G. N. Naumov et al.   CLINICAL CANCER RESEARCH

Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth

(2009) Y H Zhao et al.   ONCOGENE

Synthesis and Ribonucleotide reductase inhibitory activity of thiosemicarbazones

(2008) Kesavan Krishnan et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Role of platelet-derived growth factors in physiology and medicine

(2008) J. Andrae et al.   GENES & DEVELOPMENT

Antimitotic and Antiproliferative Activities of Chalcones: Forward Structure–Activity Relationship

(2008) Ahcène Boumendjel et al.   JOURNAL OF MEDICINAL CHEMISTRY

Prolactin and ErbB4/HER4 Signaling Interact via Janus Kinase 2 to Induce Mammary Epithelial Cell Gene Expression Differentiation

(2008) Rebecca S. Muraoka-Cook et al.   MOLECULAR ENDOCRINOLOGY

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story

(2007) Lecia V. Sequist et al.   Annual Review of Medicine

Insulin-Like Signaling, Nutrient Homeostasis, and Life Span

(2007) Akiko Taguchi et al.   Annual Review of Physiology